tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1149.360USD
-10.240-0.88%
Close 09-04 16:00ET
1.08TMarket Cap
40.73P/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-0.88%

5 Days

-0.64%

1 Month

-2.93%

6 Months

+16.42%

Year to Date

+7.47%

1 Year

+59.05%

Key Figures
1150.610Open
1158.440High
692.46KVolume
40.73P/E TTM
25.68P/E Dynamic
6.230Dividend TTM
0.07%Turnover Ratio
1159.600Prev. Close
1138.306Low
792.83MTurnover
102.13P/E Static
31.92P/B
0.54%Div Yield TTM
24.54%ROA
1292.65052wk High
0.27Volume Ratio
10.59BNet Profit
941.50MShares
28.2003EPS TTM
0.53Beta
107.65%ROE
707.58752wk Low
1.73%Amplitude
84.00%Gross Margin
1.08TMarket Cap
1.64Reward/Risk
2.26%Risk Rate

Recent

Analysis

Earnings

Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement

• Alnylam shares surged due to positive clinical data and favorable Wall Street analyst commentary. • Amvuttra demonstrated superior efficacy and strong clinical trial results for treating cardiomyopathy. • The company reports $3.71B in annual revenue and neutral technical indicators.

TradingKeyWed, Sep 2

Novo Nordisk A/S Stock (NVO) Moved Up by 3.17% on Sep 2: What Signal Does It Send?

• Novo Nordisk launched its oral weight-loss treatment in Germany and Greater China. • The company continues executing its multi-billion share repurchase program supporting shareholders. • Annual revenue reached $46.70B with net profit totaling $15.48B.

TradingKeyWed, Sep 2

Johnson & Johnson Stock (JNJ) Opened Up by 3.15% on Sep 2: Key Drivers Unveiled

• Johnson & Johnson shares rose due to defensive sector rotation into healthcare equities. • Progress on talc litigation and FDA clearances bolstered investor confidence and growth strategy. • The company posted strong quarterly earnings, raising full-year operational guidance.

TradingKeyWed, Sep 2

Mckesson Corp Stock (MCK) Moved Up by 3.13% on Sep 1: Key Drivers Unveiled

• McKesson agreed to acquire Precision Medicine Group to expand its oncology portfolio. • The company raised its quarterly dividend payout by fifteen percent. • Annual revenue reached $403.43 billion, ranking first in the industry.

TradingKeyTue, Sep 1

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

• Remibrutinib succeeded in Phase III multiple sclerosis trials, showing clinical superiority. • Novartis paused eight early-stage CAR-T trials following three patient deaths. • The company reports $56.33B annual revenue and $13.98B net profit.

TradingKeyTue, Sep 1

Biontech SE Stock (BNTX) Closed Down by 8.37% on Aug 28: What Signal Does It Send?

• BioNTech and Genentech terminated their Phase 2 autogene cevumeran colorectal cancer trial. • The independent Data Safety Monitoring Board concluded the trial lacked clinical efficacy. • BioNTech reports $3.33B in annual revenue and a net profit of $-1.32B.

TradingKeyFri, Aug 28

Eli Lilly and Co's Score

0.18vs previous score
Forecast8.12
Financial Health8.30
Technical3.02
Valuation Dimensions8.03
Institutional Confidence10.00
Risk Assessment9.06

Media Coverage

Coverage Level

49°C

Very Low
Very High
Positive+

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
1297.307Target Price
+12.87%Upside Space
Current Rating2026-092026-082026-072026-062026-052026-042026-032026-02
Strong Buy1010101010111110
Buy1717171817161614
Hold66667789
Sell11111100
Strong Sell00000000

Eli Lilly and Co Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D

Technical Indicators

Sell

Summary

Sell

Moving Average

Sell

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
7.95/6.01
Revenue / Forecast
22.97B/20.73B

Eli Lilly and Co Profile

SectorPharmaceuticals
Ticker SymbolLLY
Number of employees47000
CountryUnited States of America

Ownership

ShareholdersProportion
Lilly Endowment, Inc.9.76%
Vanguard Capital Management, LLC5.67%
PNC Investments LLC5.43%
BlackRock Institutional Trust Company, N.A.4.44%
Shareholder TypesProportion
Investment Advisor46.65%
Investment Advisor/Hedge Fund19.18%
Foundation9.76%
Research Firm2.14%

FAQs

What is the current price of Eli Lilly and Co (LLY)?

The current price of Eli Lilly and Co (LLY) is 1149.36.

What is the symbol of Eli Lilly and Co?

The ticker symbol of Eli Lilly and Co is LLY.

What is the 52-week high of Eli Lilly and Co?

The 52-week high of Eli Lilly and Co is 1292.65.

What is the 52-week low of Eli Lilly and Co?

The 52-week low of Eli Lilly and Co is 707.59.

What is the market capitalization of Eli Lilly and Co?

The market capitalization of Eli Lilly and Co is 1.08T.

Is Eli Lilly and Co (LLY) currently rated as Buy, Hold, or Sell?

According to analysts, Eli Lilly and Co (LLY) has an overall rating of Buy, with a price target of 1297.31.

What is the Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY)?

The Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY) is 28.20.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.